Clover Health Investments Corp
NASDAQ:CLOV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its Industry Average (12.9), the stock would be worth $-2.38 (231% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -9.8 | $1.82 |
0%
|
| Industry Average | 12.9 | $-2.38 |
-231%
|
| Country Average | 14.4 | $-2.66 |
-246%
|
Forward EV/EBITDA
Today’s price vs future ebitda
| Today's Enterprise Value | EBITDA | Forward EV/EBITDA | ||
|---|---|---|---|---|
|
$902.3m
|
/ |
Jan 2026
$-83.8m
|
= |
|
|
$902.3m
|
/ |
Dec 2026
$49.3m
|
= |
|
|
$902.3m
|
/ |
Dec 2027
$68.6m
|
= |
|
|
$902.3m
|
/ |
Dec 2028
$110.8m
|
= |
|
Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Clover Health Investments Corp
NASDAQ:CLOV
|
944.7m USD | -9.8 | -11 | |
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
246.6B USD | 0 | 20.5 | |
| US |
A
|
Anthem Inc
LSE:0HG8
|
74.2B USD | 0 | 13.1 | |
| US |
|
Elevance Health Inc
NYSE:ELV
|
64.1B USD | 0 | 11.3 | |
| US |
|
Humana Inc
NYSE:HUM
|
20.8B USD | 0 | 17.5 | |
| US |
|
Centene Corp
NYSE:CNC
|
16.2B USD | 0 | -2.4 | |
| US |
|
Molina Healthcare Inc
NYSE:MOH
|
7.2B USD | 3 | 15.3 | |
| US |
|
Healthequity Inc
NASDAQ:HQY
|
7B USD | 15.8 | 32.4 | |
| US |
M
|
Magellan Health Inc
F:MAH1
|
2.2B EUR | 12.9 | 8.5 | |
| US |
|
Progyny Inc
NASDAQ:PGNY
|
1.5B USD | 11.4 | 25.2 | |
| BR |
|
Odontoprev SA
BOVESPA:ODPV3
|
7.2B BRL | 8.4 | 12.4 |
Market Distribution
| Min | 0 |
| 30th Percentile | 10 |
| Median | 14.4 |
| 70th Percentile | 21.5 |
| Max | 1 767 274.1 |
Other Multiples
Clover Health Investments Corp
Glance View
Clover Health Investments Corp. embarked on a mission to transform the healthcare landscape with its innovative approach as a next-generation Medicare Advantage insurer. Born out of the need to reduce inefficiencies and enhance care, Clover Health uses its proprietary technology platform, the Clover Assistant, to arm physicians with data-driven insights that facilitate informed decision-making at the point of care. By integrating technology with healthcare delivery, Clover targets not only the evident administrative wastage but also addresses the structural challenges faced by patients and providers alike. This unique integration of digital tools with a traditional insurance model sets Clover apart in an industry ripe for disruption. Revenue for Clover Health primarily comes from Medicare Advantage premiums, where it competes by offering cost-effective plans combined with improved service. The company augments its financial model through government reimbursements tied to patient outcomes and the quality of care. Central to this strategy is the effective use of data analytics to manage patient care, reduce medical costs, and improve customer satisfaction. This alignment of financial incentives—lowering costs while enhancing patient outcomes—fuels Clover’s growth narrative, positioning it as a key player in reshaping how Medicare Advantage operates at the intersection of technology and healthcare delivery.